Literature DB >> 23823979

Angiotensin-[1-12] interacts with angiotensin type I receptors.

King H Chan1, Yi H Chen2, Ying Zhang3, Yung H Wong4, Nae J Dun5.   

Abstract

Angiotensin-(1-12) [Ang-(1-12)], a newer member of angiotensin peptides, is proposed to be converted enzymatically to angiotensin I (Ang I) and to angiotensin II (Ang II); the latter being the bioactive peptide. We studied the Ang-(1-12) and Ang II responses in COS-7 cells or CHO cells transfected with 5 μg AT1R by monitoring [Ca(2+)]i using the Fluo-4. Ang II (1 pM-1 μM) and Ang-(1-12) (5 pM-5 μM) increased [Ca(2+)]i with an EC50 of 0.19 nM and 24 nM in COS-7 cells; and 0.65 nM and 28.7 nM in CHO cells. The AT1R antagonist losartan (1 nM-10 μM) suppressed [Ca(2+)]i induced by Ang-(1-12) and Ang II. In CHO cells transfected with 5 μg AT2R, Ang II (1 pM-1 μM) increased [Ca(2+)]i, with an EC50 of 9.68 nM; whereas, Ang-(1-12) (5 pM-5 μM) failed to elicit a significant change in [Ca(2+)]i. In CHO cells transfected with AT1R, Ang-(1-12) stimulated ERK phosphorylation with a potency 300-fold less than that of Ang II. To evaluate the activity of Ang-(1-12) on native AT1R, whole cell patch recordings were made from neurons in the rat hypothalamic slices. Ang II or Ang-(1-12) ejected by pressure from a micropipette elicited a membrane depolarization; the latter was blocked by losartan (10 μM), and not affected by the AT2R antagonist PD123319 (10 μM), nor by the angiotensin converting enzyme inhibitor captopril (10 μM). Our result shows that Ang-(1-12) may produce its biological activity by acting directly on AT1R, albeit at a concentration higher than that of Ang II.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACE inhibitor; Angiotensin II; G-protein; Hypothalamus

Mesh:

Substances:

Year:  2013        PMID: 23823979      PMCID: PMC3823637          DOI: 10.1016/j.neuropharm.2013.06.022

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  32 in total

1.  PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation.

Authors:  Quy N Diep; Farhad Amiri; Rhian M Touyz; Jeffrey S Cohn; Dierk Endemann; Mario Fritsch Neves; Ernesto L Schiffrin
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Plasma and tissue levels of proangiotensin-12 and components of the renin-angiotensin system (RAS) following low- or high-salt feeding in rats.

Authors:  Sayaka Nagata; Johji Kato; Kenji Kuwasako; Kazuo Kitamura
Journal:  Peptides       Date:  2010-02-19       Impact factor: 3.750

Review 3.  Angiotensin IV in the central nervous system.

Authors:  Oliver von Bohlen und Halbach
Journal:  Cell Tissue Res       Date:  2002-11-22       Impact factor: 5.249

4.  Incorporation of Galpha(z)-specific sequence at the carboxyl terminus increases the promiscuity of galpha(16) toward G(i)-coupled receptors.

Authors:  S M Mody; M K Ho; S A Joshi; Y H Wong
Journal:  Mol Pharmacol       Date:  2000-01       Impact factor: 4.436

5.  Cardiovascular actions of angiotensin-(1-12) in the hypothalamic paraventricular nucleus of the rat are mediated via angiotensin II.

Authors:  Vineet C Chitravanshi; Archana Proddutur; Hreday N Sapru
Journal:  Exp Physiol       Date:  2011-11-28       Impact factor: 2.969

6.  Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus.

Authors:  Amy C Arnold; Katsunori Isa; Hossam A Shaltout; Manisha Nautiyal; Carlos M Ferrario; Mark C Chappell; Debra I Diz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

7.  A role for PYK2 in regulation of ERK1/2 MAP kinases and PI 3-kinase by ANG II in vascular smooth muscle.

Authors:  P Rocic; G Govindarajan; A Sabri; P A Lucchesi
Journal:  Am J Physiol Cell Physiol       Date:  2001-01       Impact factor: 4.249

8.  Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney.

Authors:  Brian M Westwood; Mark C Chappell
Journal:  Peptides       Date:  2012-04-03       Impact factor: 3.750

9.  Carboxypeptidases A1 and A2 from the perfusate of rat mesenteric arterial bed differentially process angiotensin peptides.

Authors:  Hugo J V Pereira; Laura L Souza; Claudio M Costa-Neto; Maria Cristina O Salgado; Eduardo B Oliveira
Journal:  Peptides       Date:  2011-12-09       Impact factor: 3.750

10.  Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue.

Authors:  Sarfaraz Ahmad; Tony Simmons; Jasmina Varagic; Norihito Moniwa; Mark C Chappell; Carlos M Ferrario
Journal:  PLoS One       Date:  2011-12-13       Impact factor: 3.240

View more
  4 in total

1.  Functional and molecular evidence for expression of the renin angiotensin system and ADAM17-mediated ACE2 shedding in COS7 cells.

Authors:  Nadja Grobe; Mauricio Di Fulvio; Nada Kashkari; Harshita Chodavarapu; Hari K Somineni; Richa Singh; Khalid M Elased
Journal:  Am J Physiol Cell Physiol       Date:  2015-03-04       Impact factor: 4.249

2.  Critical role of the chymase/angiotensin-(1-12) axis in modulating cardiomyocyte contractility.

Authors:  Tiankai Li; Xiaowei Zhang; Heng-Jie Cheng; Zhi Zhang; Sarfaraz Ahmad; Jasmina Varagic; Weimin Li; Che Ping Cheng; Carlos M Ferrario
Journal:  Int J Cardiol       Date:  2018-04-21       Impact factor: 4.164

Review 3.  Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Jasmina Varagic; Che Ping Cheng; Leanne Groban; Hao Wang; James F Collawn; Louis J Dell Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-27       Impact factor: 4.733

Review 4.  Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.

Authors:  Santiago Reyes; Jasmina Varagic; Sarfaraz Ahmad; Jessica VonCannon; Neal D Kon; Hao Wang; Leanne Groban; Che Ping Cheng; Louis J Dell'Italia; Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2017-02       Impact factor: 5.369

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.